Pandemic Influenza Sample Clauses

Pandemic Influenza. Within the UK National Risk Register, Pandemic Influenza (Flu) is regarded as the most significant risk to the UK in light of its impact, however until the pandemic emerges its effect cannot be predicted with any degree of certainty. Within the West Midlands Conurbation Risk Register it has been given an overall risk ratingVery High’. An influenza pandemic occurs when a new influenza virus, which people have no immunity to, emerges and starts spreading as easily as normal influenza. Unlike seasonal flu, Pandemic Flu can affect anyone and therefore has the potential to affect a large proportion of the population over a short period of time. Whilst influenza pandemics have been relatively infrequent over the past century, a new pandemic could emerge at any time. The H1N1 flu pandemic which emerged in 2009 turned out to be a relatively mild illness for most of those affected. However, 457 people are known to have died in England and Wales, including a disproportionate number in children and pregnant women. Whilst the 2009 influenza pandemic proved much milder, the next pandemic may not be so. The WHO estimates that the next pandemic could lead to between 2 million to 7.4 million deaths globally. National Planning Assumptions estimate that an Influenza pandemic is likely to affect up to roughly half the population who may become symptomatic and it is estimated that 30% of these may require assessment and treatment. Between 1% and 4% of symptomatic patients will require hospital care, depending on how severe the illness caused by the virus is. It is difficult to predict the most vulnerable groups who would be most affected by a pandemic as this will directly depend on the strain of the pathogen involved and its expected target population. It is fair to assume all age groups will be susceptible. Especially susceptible to more severe illness will be immuno-compromised individuals, the elderly, pregnant women and those with underlying respiratory, cardiac, renal and hepatic diseases and deaths may occur in all age groups. It also is impossible to give precise figures of the number of deaths that can be expected however, on a precautionary basis, local planners should prepare to cope locally with between 210,000 – 315,000 additional deaths across the UK (possibly up to 18,000 across West Midlands) over a 15 week period. In a less widespread and lower impact influenza pandemic, the number of additional deaths would be lower. Service delivery will be affected by la...
AutoNDA by SimpleDocs

Related to Pandemic Influenza

  • Influenza Vaccine Upon recommendation of the Medical Officer of Health, all employees shall be required, on an annual basis to be vaccinated and or to take antiviral medication for influenza. If the costs of such medication are not covered by some other sources, the Employer will pay the cost for such medication. If the employee fails to take the required medication, she may be placed on an unpaid leave of absence during any influenza outbreak in the home until such time as the employee has been cleared by the public health or the Employer to return to the work environment. The only exception to this would be employees for whom taking the medication will result in the employee being physically ill to the extent that she cannot attend work. Upon written direction from the employee’s physician of such medical condition in consultation with the Employer’s physician, (if requested), the employee will be permitted to access their sick bank, if any, during any outbreak period. If there is a dispute between the physicians, the employee will be placed on unpaid leave. If the employee gets sick as a reaction to the drug and applies for WSIB the Employer will not oppose the application. If an employee is pregnant and her physician believes the pregnancy could be in jeopardy as a result of the influenza inoculation and/or the antiviral medication she shall be eligible for sick leave in circumstances where she is not allowed to attend at work as a result of an outbreak. This clause shall be interpreted in a manner consistent with the Ontario Human Rights Code.

  • Pandemic An epidemic that spreads over a wide area, crossing borders and defined as a pandemic by the World Health Organisation (WHO) and/or by the competent local authorities of the country where the loss occurred. Quarantine Isolation of the person, in the event of suspected illness or proven illness, decided by a competent local authority, in order to avoid a risk of spreading said illness in the context of an epidemic or pandemic.

  • Hepatitis B Vaccine Where the Hospital identifies high risk areas where employees are exposed to Hepatitis B, the Hospital will provide, at no cost to the employees, a Hepatitis B vaccine.

  • Influenza Vaccination The parties agree that influenza vaccinations may be beneficial for patients and employees. Upon a recommendation pertaining to a facility or a specifically designated area(s) thereof from the Medical Officer of Health or in compliance with applicable provincial legislation, the following rules will apply:

  • Infectious Diseases The Employer and the Union desire to arrest the spread of infectious diseases in the nursing home. To achieve this objective, the Joint Health and Safety Committee may review and offer input into infection control programs and protocols including surveillance, outbreak control, isolation, precautions, worker education and training, and personal protective equipment. The Employer will provide training and ongoing education in communicable disease recognition, use of personal protective equipment, decontamination of equipment, and disposal of hazardous waste.

  • Biological Samples If so specified in the Protocol, Institution and Principal Investigator may collect and provide to Sponsor or its designee Biological Samples (“Biological Samples”). 12.2.

  • Infectious Disease Where an employee produces documentary evidence that:

  • TRAFFIC INFRACTIONS The State will not be liable for any expense incurred by the Contractor for any parking fees or as a consequence of any traffic infraction or parking violations attributable to employees of the Contractor.

  • Organ Transplants This plan covers organ and tissue transplants when ordered by a physician, is medically necessary, and is not an experimental or investigational procedure. Examples of covered transplant services include but are not limited to: heart, heart-lung, lung, liver, small intestine, pancreas, kidney, cornea, small bowel, and bone marrow. Allogenic bone marrow transplant covered healthcare services include medical and surgical services for the matching participant donor and the recipient. However, Human Leukocyte Antigen testing is covered as indicated in the Summary of Medical Benefits. For details see Human Leukocyte Antigen Testing section. This plan covers high dose chemotherapy and radiation services related to autologous bone marrow transplantation to the extent required under R.I. Law § 27-20-60. See Experimental or Investigational Services in Section 3 for additional information. To speak to a representative in our Case Management Department please call 1-401- 000-0000 or 1-888-727-2300 ext. 2273. The national transplant network program is called the Blue Distinction Centers for Transplants. SM For more information about the Blue Distinction Centers for TransplantsSM call our Customer Service Department or visit our website. When the recipient is a covered member under this plan, the following services are also covered: • obtaining donated organs (including removal from a cadaver); • donor medical and surgical expenses related to obtaining the organ that are integral to the harvesting or directly related to the donation and limited to treatment occurring during the same stay as the harvesting and treatment received during standard post- operative care; and • transportation of the organ from donor to the recipient. The amount you pay for transplant services, for the recipient and eligible donor, is based on the type of service.

  • Human Leukocyte Antigen Testing This plan covers human leukocyte antigen testing for A, B, and DR antigens once per member per lifetime to establish a member’s bone marrow transplantation donor suitability in accordance with R.I. General Law §27-20-36. The testing must be performed in a facility that is: • accredited by the American Association of Blood Banks or its successors; and • licensed under the Clinical Laboratory Improvement Act as it may be amended from time to time. At the time of testing, the person being tested must complete and sign an informed consent form that also authorizes the results of the test to be used for participation in the National Marrow Donor program.

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!